Resmed reports ‘strong finish’

SAN DIEGO – Resmed reported revenue growth of 10% to $1.3 billion for the fourth quarter of fiscal year 2025 compared to the same period the previous year.

The company reported revenue growth of 10% to $5.1 billion for the full year 2025 compared to the previous year.

“Our strong finish to fiscal year 2025 reflects ongoing momentum across our business, driven by robust global demand for our market-leading sleep and breathing health devices, as well as our expanding digital health ecosystem,” said Resmed Chairman and CEO Mick Farrell.

Fourth quarter highlights:

• Gross margin improved 230 bps to 60.8%; non-GAAP gross margin improved 230 bps to 61.4%
• Income from operations increased 19%; non-GAAP income from operations up 19%
• Operating cash flow of $539 million
• Diluted earnings per share of $2.58; non-GAAP diluted earnings per share of $2.55

“In the fourth quarter, we delivered 10% headline revenue growth, 230 basis points in non-GAAP gross margin expansion and 23% non-GAAP EPS growth,” Farrell said. “These results are a testament to the value that our best-in-class solutions deliver to our customers and the unwavering dedication of our global team. Our connected care platform continues to set the standard for digital health innovation, empowering millions of people to take control of their sleep and breathing health with hardware, software and health care solutions delivered in their own homes.”

Full-year highlights:

• Gross margin improved 270 bps to 59.4%; non-GAAP gross margin improved 230 bps to 60.0%
• Income from operations increased 28%; non-GAAP income from operations up 19%
• Operating cash flow of $1.8 billion
• Diluted earnings per share of $9.51; non-GAAP diluted earnings per share of $9.55

“As we move into fiscal year 2026, we will continue to invest in innovation, scale our digital health capabilities, and partner with patients, providers, payers and policymakers to ensure more people around the world have access to the care they need to sleep better, breathe better, and live longer and healthier lives,” Farrell said.

Among the highlights for the fourth quarter, Resmed says, was its acquisition of VirtuOx. The company said with VirtuOx’s at-home diagnostic services, it will be better positioned to support patients earlier in their journey and help health care providers and home care companies deliver care in a simpler, more connected way.